Low-dose dasatinib rescues cardiac function in Noonan syndrome.

Abstract

Noonan syndrome (NS) is a common autosomal dominant disorder that presents with short stature, craniofacial dysmorphism, and cardiac abnormalities. Activating mutations in the PTPN11 gene encoding for the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase-2 (SHP2) causes approximately 50% of NS cases. In contrast, NS with multiple lentigines (NSML) is caused by mutations that inactivate SHP2, but it exhibits some overlapping abnormalities with NS. Protein zero-related (PZR) is a SHP2-binding protein that is hyper-tyrosyl phosphorylated in the hearts of mice from NS and NSML, suggesting that PZR and the tyrosine kinase that catalyzes its phosphorylation represent common targets for these diseases. We show that the tyrosine kinase inhibitor, dasatinib, at doses orders of magnitude lower than that used for its anticancer activities inhibited PZR tyrosyl phosphorylation in the hearts of NS mice. Low-dose dasatinib treatment of NS mice markedly improved cardiomyocyte contractility and functionality. Remarkably, a low dose of dasatinib reversed the expression levels of molecular markers of cardiomyopathy and reduced cardiac fibrosis in NS and NSML mice. These results suggest that PZR/SHP2 signaling is a common target of both NS and NSML and that low-dose dasatinib may represent a unifying therapy for the treatment of PTPN11-related cardiomyopathies.

• Authors: Jae-Sung Yi, Yan Huang, Andrea T Kwaczala, Ivana Y Kuo, Barbara E Ehrlich, Stuart G Campbell, Frank J Giordano, Anton M Bennett
• Journal: JCI insight (JCI Insight) Vol. 1 Issue 20 Pg. e90220 (12 08 2016) ISSN: 2379-3708 [Print] United States
• PMID: 27942593 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Intracellular Signaling Peptides and Proteins
• MPZL1 protein, mouse
• Phosphoproteins
• Protein Tyrosine Phosphatase, Non-Receptor Type 11
• Ptpn11 protein, mouse
• Dasatinib

Topics

• Animals
• Dasatinib (administration & dosage, pharmacology)
• Fibrosis
• Intracellular Signaling Peptides and Proteins (metabolism)
• Mice
• Mice, Inbred C57BL
• Mutation
• Myocardium (pathology)
• Myocytes, Cardiac (drug effects)
• Noonan Syndrome (drug therapy)
• Phosphoproteins (metabolism)
• Phosphorylation
• Protein Tyrosine Phosphatase, Non-Receptor Type 11 (metabolism)
• Signal Transduction